Sichuan Deebio Pharmaceutical Co., Ltd accepted the official GMP compliance inspection from Japan PMDA from 8.25 to 8.26 in 2022. The GMP audit team consisted of two auditors led by experienced veteran experts and carried out a two-day remote audit. The experts of the inspection team conducted a comprehensive inspection of Deebio’s quality management system, production management system, on-site operation, laboratory management, related supporting facilities and equipment, and maintenance of public systems.
 
Through the inspection, the experts of the inspection team have unanimously affirmed and highly recognized Deebio’s GMP quality management system. Finally, Deebio has successfully passed the official GMP certification of Japan’s PMDA!

PMDA (Pharmaceuticals and Medical Devices Agency) is a Japanese agency responsible for technical review of drugs and medical devices. It is functionally similar to the FDA in the United States and the NMPA in China.

Deebio has passed the EU-GMP and Chinese GMP certification. The successful passing of Japan’s PMDA certification marks a phased victory in Deebio’s global strategy!